Robert Hoffman

Polaris Group is a sales, marketing and consulting firm with experience in bringing new residential real estate to market in the San Francisco Bay Area and Southern California. Polaris Group has three distinct divisions: Polaris Analytics, Polaris Marketing and Polaris Sales. From land acquisition, market research and entitlements, to architectural review, brand development and escrow coordination, Polaris Group analyzes each new home community and attempts to maximize builder opportunities. Their approach is based on constant evaluation of pricing trends, new product supply pipelines, construction pricing and market conditions.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT.

CombiMatrix Corp. engages in the provision of clinical diagnostic services. It offers cytogenomic testing for preimplantation genetic testing, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. The company was founded in October 1995 and is headquartered in Irvine, CA.

Telik, Inc. is an innovative biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. Its TELINTRA product is used for treatment of cytopenias due to myelodysplastic syndrome and chemotherapy. The company's product candidates were discovered using its proprietary drug discovery technology TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Telik was founded in September 1988 and is headquartered in Palo Alto, CA.

MabVax Therapeutics Holdings, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing innovative vaccine and monoclonal antibody-based therapeutics for the diagnosis and treatment of cancer. The company was founded on July 8, 2014 and is headquartered in San Diego, CA.

Zeta Acquisition Corp. III operates as a blank check company. It was organized as a vehicle to investigate and, if such investigation warrants, acquire a target company or business seeking the perceived advantages of being a publicly held corporation. The firm will not restrict its potential candidate target companies to any specific business, industry or geographical location and, thus, may acquire any type of business. The company was founded on November 16, 2007 and is headquartered in Des Moines, IA.

Document Sciences Corp. developed software for customer communications management solutions. Its products included xPression and Autograph, which enable automated publishing solutions for insurance, financial services, healthcare, manufacturing, distribution, government, and commercial outsourcing industries. The company was founded in 1991 and was headquartered in Carlsbad, CA.

Innovus Pharmaceuticals, Inc. engages in the commercialization, licensing, and development of non-prescription medicine, and consumer care products for health and vitality, and respiratory diseases. Its products focuses in six main categories, including sexual health, pain management, general muscle health, respiratory, sleep, and diabetic care. The company was founded on January 15, 1959 and is headquartered in Englewood, CO.

Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA.

ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.